Onychomycosis Market Forecast to Grow at 4.7% CAGR from 2024 to 2031 | SkyQuest Technology
18 sept. 2024 08h30 HE
|
SkyQuest Technology Consulting Pvt. Ltd.
Westford, USA, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Onychomycosis Market size was valued at USD 3.5 billion in 2023 to USD 5.05 billion by 2031, at a CAGR of 4.7% during the forecast period...
Onychomycosis Market Growing at 4.6% CAGR to Hit USD 5,689.46 Million by 2032 | Polaris Market Research (PMR)
21 août 2024 08h50 HE
|
Polaris Market Research & Consulting LLP
New York, USA, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Market Overview: The onychomycosis market was estimated at USD 3,798.92 million in 2023. The market valuation is expected to be USD 5,689.46...
Zylö Receives $600,000 NIH Phase I Grant to Develop a Novel Therapeutic to Treat Onychomycosis (Nail Fungus)
19 août 2022 09h00 HE
|
Zylö Therapeutics
Funds to be used to optimize a formulation and prepare for scale-up and IND-enabling studies GREENVILLE, SC, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the Z-pod®...
Onychomycosis Treatment Market Anticipated to Expand with a CAGR of 7% During 2021-2031 Amidst Increased Awareness & Improvement in Healthcare Infrastructure - Future Market Insights, Inc.
06 juil. 2022 09h30 HE
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, July 06, 2022 (GLOBE NEWSWIRE) -- As per the recent edition of the Onychomycosis Treatment Market report, ESOMAR-certified market research and consulting firm Future Market Insights...
SB208 Increases Daily Nail Growth Rate over Four Weeks of Treatment
17 mai 2018 08h05 HE
|
Novan, Inc.
MORRISVILLE, N.C., May 17, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that data from the Company’s onychomycosis development program with SB208 gel...
Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference
11 janv. 2018 09h10 HE
|
Novan, Inc.
MORRISVILLE, N.C., Jan. 11, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that Phase 2 efficacy and safety data for SB208, a topical, silicone-based...
Novan Reports Positive Topline Results with SB208 in Phase 2 Trial
12 avr. 2017 06h06 HE
|
Novan, Inc.
MORRISVILLE, N.C., April 12, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced positive topline results from the Company’s Phase 2 clinical trial with...